Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -695.56% is 563% below its 5-year average of -104.93%, near the low end of its 5-year range (-867.84%–-9.45%).
As of the fiscal period ended Tuesday, June 30, 2026. 5.59% below its 12-month average of -658.74%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -695.56%.
RETURN ON EQUITY (ROE)
-695.56%
RETURN ON EQUITY (ROE) AVG TTM
-658.74%
RETURN ON EQUITY (ROE) AVG 3Y
-348.12%
RETURN ON EQUITY (ROE) AVG 5Y
-104.93%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-5.59%
CURRENT VS 3Y AVG
-99.81%
CURRENT VS 5Y AVG
-562.88%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-37.66%
median of 436 covered companies
CURRENT VS SECTOR MEDIAN
-1746.95%
vs the sector median at left
Greenwich LifeSciences, Inc.
Market Cap
$248.21M
Return on Equity (ROE)
-695.56%
TTM Avg
-658.74%
3Y Avg
-348.12%
5Y Avg
-104.93%
Market Cap
$247.45M
Return on Equity (ROE)
-27.27%
TTM Avg
-92.43%
3Y Avg
-64.95%
5Y Avg
-57.80%
Market Cap
$247.23M
Return on Equity (ROE)
-59.27%
TTM Avg
-136.66%
3Y Avg
-113.26%
5Y Avg
-53.68%
Market Cap
$245.65M
Return on Equity (ROE)
N/A
TTM Avg
35.05%
3Y Avg
64.68%
5Y Avg
-167.54%
Market Cap
$251.64M
Return on Equity (ROE)
N/A
TTM Avg
-125.28%
3Y Avg
-42.20%
5Y Avg
-43.41%
Market Cap
$244.25M
Return on Equity (ROE)
-118.58%
TTM Avg
62.37%
3Y Avg
-376.78%
5Y Avg
-340.60%
Market Cap
$239.89M
Return on Equity (ROE)
-31.55%
TTM Avg
-30.05%
3Y Avg
-33.97%
5Y Avg
-37.95%
Market Cap
$239.45M
Return on Equity (ROE)
-25.20%
TTM Avg
-25.82%
3Y Avg
5.12%
5Y Avg
5.12%
Market Cap
$259.30M
Return on Equity (ROE)
-38.33%
TTM Avg
-61.68%
3Y Avg
-393.03%
5Y Avg
-278.88%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | $248.21M | -695.56% | -658.74% | -348.12% | -104.93% |
| InflaRx N.V. (IFRX)vs › | $247.45M | -27.27% | -92.43% | -64.95% | -57.80% |
| Invivyd, Inc. (IVVD)vs › | $247.23M | -59.27% | -136.66% | -113.26% | -53.68% |
| Galectin Therapeutics Inc. (GALT)vs › | $245.65M | N/A | 35.05% | 64.68% | -167.54% |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $251.64M | N/A | -125.28% | -42.20% | -43.41% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $244.25M | -118.58% | 62.37% | -376.78% | -340.60% |
| High Tide Inc. (HITI)vs › | $239.89M | -31.55% | -30.05% | -33.97% | -37.95% |
| BioAge Labs Inc. (BIOA)vs › | $239.45M | -25.20% | -25.82% | 5.12% | 5.12% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.30M | -38.33% | -61.68% | -393.03% | -278.88% |
| Biodesix, Inc. (BDSX)vs › | $236.56M | -303.61% | 612.49% | -57.80% | -87.69% |
ROE
-695.6%
ROA
-244.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -695.56% |
| 2026-03-31 | -412.83% |
| 2025-09-30 | -867.84% |
| 2024-12-31 | -623.07% |
| 2024-09-30 | -210.64% |
| 2024-06-30 | -173.92% |
| 2024-03-31 | -180.44% |
| 2023-12-31 | -132.71% |
| 2023-09-30 | -100.94% |
| 2023-06-30 | -83.22% |
| 2023-03-31 | -68.30% |
| 2022-12-31 | -59.22% |
| 2022-09-30 | -47.99% |
| 2022-06-30 | -35.00% |
| 2022-03-31 | -30.46% |
| 2021-12-31 | -17.03% |
| 2021-09-30 | -11.81% |
| 2021-06-30 | -9.45% |
| 2021-03-31 | -7.45% |
| 2020-12-31 | -6.74% |
| 2020-09-30 | -22.51% |
